Legal & General Group Plc Cuts Stake in OrthoPediatrics Corp. (NASDAQ:KIDS)

Legal & General Group Plc decreased its holdings in OrthoPediatrics Corp. (NASDAQ:KIDS) by 16.2% in the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 16,942 shares of the company’s stock after selling 3,275 shares during the period. Legal & General Group Plc owned approximately 0.07% of OrthoPediatrics worth $393,000 as of its most recent SEC filing.

A number of other institutional investors also recently made changes to their positions in KIDS. Barclays PLC boosted its stake in shares of OrthoPediatrics by 319.3% in the 3rd quarter. Barclays PLC now owns 25,298 shares of the company’s stock valued at $686,000 after purchasing an additional 19,264 shares in the last quarter. Geode Capital Management LLC boosted its stake in shares of OrthoPediatrics by 2.1% in the 3rd quarter. Geode Capital Management LLC now owns 391,492 shares of the company’s stock valued at $10,615,000 after purchasing an additional 7,972 shares in the last quarter. Harbor Capital Advisors Inc. boosted its stake in shares of OrthoPediatrics by 1.9% in the 4th quarter. Harbor Capital Advisors Inc. now owns 251,588 shares of the company’s stock valued at $5,832,000 after purchasing an additional 4,728 shares in the last quarter. R Squared Ltd purchased a new stake in OrthoPediatrics during the 4th quarter valued at $48,000. Finally, Rhumbline Advisers boosted its position in OrthoPediatrics by 4.1% during the 4th quarter. Rhumbline Advisers now owns 26,411 shares of the company’s stock valued at $612,000 after buying an additional 1,042 shares during the period. Hedge funds and other institutional investors own 69.05% of the company’s stock.

Insider Activity at OrthoPediatrics

In related news, insider Gregory A. Odle sold 5,359 shares of OrthoPediatrics stock in a transaction dated Tuesday, March 18th. The shares were sold at an average price of $24.86, for a total transaction of $133,224.74. Following the completion of the transaction, the insider now directly owns 148,788 shares of the company’s stock, valued at $3,698,869.68. This trade represents a 3.48 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CEO David R. Bailey sold 6,620 shares of OrthoPediatrics stock in a transaction dated Tuesday, March 18th. The shares were sold at an average price of $24.86, for a total transaction of $164,573.20. Following the transaction, the chief executive officer now directly owns 319,155 shares of the company’s stock, valued at approximately $7,934,193.30. This trade represents a 2.03 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 23,732 shares of company stock valued at $589,978 in the last three months. Company insiders own 31.80% of the company’s stock.

Wall Street Analysts Forecast Growth

KIDS has been the subject of several analyst reports. Needham & Company LLC reissued a “buy” rating and set a $42.00 price target on shares of OrthoPediatrics in a research report on Wednesday, April 9th. Lake Street Capital initiated coverage on shares of OrthoPediatrics in a research report on Monday, April 7th. They set a “buy” rating and a $37.00 price target for the company. Stifel Nicolaus dropped their price target on shares of OrthoPediatrics from $40.00 to $32.00 and set a “buy” rating for the company in a research report on Wednesday, March 5th. Finally, Truist Financial cut their target price on shares of OrthoPediatrics from $26.00 to $24.00 and set a “hold” rating on the stock in a research note on Friday, April 11th. One investment analyst has rated the stock with a hold rating and four have issued a buy rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $37.00.

OrthoPediatrics Trading Down 3.4 %

Shares of KIDS opened at $20.82 on Thursday. The firm’s 50-day moving average price is $23.32 and its 200-day moving average price is $24.36. The firm has a market capitalization of $505.66 million, a price-to-earnings ratio of -16.93 and a beta of 1.17. The company has a current ratio of 7.17, a quick ratio of 3.68 and a debt-to-equity ratio of 0.19. OrthoPediatrics Corp. has a 1-year low of $20.25 and a 1-year high of $35.99.

OrthoPediatrics (NASDAQ:KIDS) last announced its earnings results on Tuesday, March 4th. The company reported ($0.29) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.33) by $0.04. The firm had revenue of $52.67 million for the quarter, compared to analyst estimates of $51.16 million. OrthoPediatrics had a negative net margin of 15.00% and a negative return on equity of 5.78%. During the same quarter in the previous year, the firm posted ($0.23) EPS. Sell-side analysts anticipate that OrthoPediatrics Corp. will post -0.93 EPS for the current year.

OrthoPediatrics Company Profile

OrthoPediatrics Corp., a medical device company, engages in designing, developing, and marketing anatomically appropriate implants, instruments, and specialized braces for children with orthopedic conditions in the United States and internationally. The company offers pediatric trauma and deformity correction products; scoliosis procedures for the treatment of spinal deformity; and sports medicine and other products.